Description: The educational program provides insights on managing CLL from a Canadian and International perspective. The content has been designed to improve the knowledge and skills of clinicians who manage patients with CLL . Practical treatment strategies including evidence based best practices aligned with guideline recommendations will be discussed. Presenters will engage in a clinical exchange to address key clinical questions in CLL.
Peter Hillmen, MB ChB, FRCP, FRCPath, PhD
Dr. Carolyn Owen, FRCPC
At the end of the session participants will be able to:
• Determine patient characteristics from recently reported and ongoing clinical trials conducted among patients with CLL
• Evaluate safety and efficacy data from recent clinical trials that impact practice in the care of patients with CLL
• Place recent clinical trial results in their proper clinical context given evolving treatment paradigms in CLL management
Target Audience: Hematologists
CanMEDS: Medical Experts (the integrating role)
Declaration of Conflict of Interest:
Dr. HIllmen: AstraZeneca, Janssen, Beigene, Roche, Sobi and AbbVie, honoraria for speaking. Advisory board member - Astra Zeneca, Janssen, Abbvie, Beigene, Roche, Sobi. Chief Investigator of NCRI Trials: Janssen, Abbvie, Roche.
Dr. Owen: Abbvie-honoraria. AstraZeneca-Advisory Board honoraria. Beigene-grant/clinical trial honoraria. Patent on drug/product/service honoraria - Janssen. Honoraria-Roche.
Accreditation:This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists (CAP-AC). You may claim a maximum of 1.0 hours.
This webinar was co-developed with Astra Zeneca and the CHS and was planned to achieve scientific integrity, objectivity and balance. This webinar is for CHS members and offered on a complimentary basis.